Cost-per-responder analysis of guselkumab versus ixekizumab with the use of efficacy results from pivotal clinical trials in patients with moderate to severe plaque psoriasis
2018 ◽
Vol 79
(3)
◽
pp. AB88
Keyword(s):
2018 ◽
Vol 79
(3)
◽
pp. AB89
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Vol 1
◽
pp. s6
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 22
(3)
◽
pp. 138-143
◽